Inhibition of aromatase activity in human placental microsomes by 13-retro-antiprogestins

Mifepristone (RU 486), used clinically for the termination of early pregnancy, and its acetyl and 13-retro (13α) analogs show potent antiproliferative effects against estrogen-dependent human breast tumors and endometriosis. However, there has been no report on direct inhibition of aromatase by anti...

Full description

Saved in:
Bibliographic Details
Published inSteroids Vol. 60; no. 2; pp. 234 - 238
Main Authors Shimizu, Yukiko, Yarborough, Carol P., Elger, Walter, Chwalisz, Krzysztof, Osawa, Yoshio
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.02.1995
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Mifepristone (RU 486), used clinically for the termination of early pregnancy, and its acetyl and 13-retro (13α) analogs show potent antiproliferative effects against estrogen-dependent human breast tumors and endometriosis. However, there has been no report on direct inhibition of aromatase by antiprogesterones. Aromatase inhibitors have been shown to be effective against estrogen-dependent breast cancer. We evaluated the inhibition of aromatase by various antiprogestins (ZK 112.993, ZK 98.734, ZK 114.043, ZK 98.299, and ZK 114.863). Human placental microsomes were incubated with [1β- 3H,4- 14C]androstenedione (3–114 nM) in the presence of NADPH, with or without putative inhibitors (10–200 μM). Aromatase activity was assessed by tritium release to water from the 1β-position of the substrate. ZK 112.993 and ZK 98.734 did not show any inhibitory effect. The statistical analysis of the data using standard errors was obtained from replicate experiments. ZK 114.043 showed slight inhibition with a K i of 54.8 ± 6.4 μM (m ± SE, n = 6) against androstenedione aromatization. The two 13-retro-steroids, ZK 98.299 and ZK 114.863, showed aromatase inhibition with K i values of 19.0 ± 1.5 μM (n = 7) and 12.7 ± 0.94 μM (n = 7), respectively, which is weak with respect to some known potent inhibitors, but significant when compared with the other antiprogestins which were tested. The results suggest that the unnatural 13-retro-antiprogestin conformation may have a better fit to the aromatase active site than the natural 13β-antiprogestin conformation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0039-128X
1878-5867
DOI:10.1016/0039-128X(94)00043-C